Main findings
We found improved PFS as a benefit of BEV throughout triweekly in the
dosage range of 7.5–15 mg/kg, which is consistent with results of
independent phase 3 trials assessing front-line
therapy7,8 and real-world data.15−17PFI <6 m independently predicted shorter PFS and OS, but BEV
may reduce platinum-resistant relapse; these findings are in concordance
with the prospective single-arm results in JGOG3022.17